Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Pneumococcal conjugate vaccines: choice of schedule and product development

  • Lee, Jin (Department of Pediatrics, Hanil General Hospital)
  • Received : 2019.12.31
  • Accepted : 2020.04.25
  • Published : 2020.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Global Health. 2018;6:e744-57. https://doi.org/10.1016/S2214-109X(18)30247-X
  2. VIEW-hub Report: Global Vaccine Introduction and Implementation [Internet]. Baltimore (MD): International Vaccine Access Center (IVAC); Johns Hopkins Bloomberg School of Public Health; 2019 Mar [cited 2019 Dec 1]. Available from: https://www.jhsph.edu/ivac/wp-content/uploads/2019/05/VIEW-hub_Report_Mar2019.pdf.
  3. WHO Position Paper on Pneumococcal conjugate vaccines in infants and children under 5 years of age, February 2019 [Internet]. Geneva (Switzerland): World Health Organization; 2019 Feb [cited 2019 Dec 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/310968/WER9408.pdf?ua=1.
  4. Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33:S109-18. https://doi.org/10.1097/inf.0000000000000078
  5. Loo JD, Conklin L, Fleming-Dutra KE, Deloria Knoll M, Park DE, Kirk J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J 2014;33 Suppl 2(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules):S140-51. https://doi.org/10.1097/INF.0000000000000082
  6. Shin J, Teeratakulpisarn J, Puthanakit T, Theerawit T, Ryu JH, Shin J, et al. Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind activecontrolled trial. Clin Exp Pediatr 2020;63:265. https://doi.org/10.3345/cep.2019.01067
  7. Scott P, Rutjes AW, Bermetz L, Robert N, Scott S, Lourenco T, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 2011;29:9711-21. https://doi.org/10.1016/j.vaccine.2011.07.042
  8. Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine 2018;36:6883-91. https://doi.org/10.1016/j.vaccine.2018.02.113